You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Equiscreen.

AVAI Is Moving Fast in the Longevity Race—And This Klotho Breakthrough Could Be the Early Signal Investors Don’t Want to Miss

Avaí Bio, Inc. (OTCQB: AVAI) just hit a key inflection point—launching GMP production of its Master Cell Bank for its α-Klotho anti-aging program with Austrianova. That may sound technical, but here’s what it really means: the company is stepping out of concept mode and into real-world production infrastructure.

By building the foundation required to scale a “longevity protein” therapy, AVAI) is positioning itself in one of biotech’s hottest frontiers—treating aging and chronic disease at the biological level, not just managing symptoms.

This isn’t a niche opportunity. Aging, diabetes, and chronic disease represent massive, trillion-dollar global markets—and AVAI is developing a platform designed to plug directly into that demand with long-term, cell-based solutions. Early-stage biotech is always high risk, but it’s also where the biggest upside lives—and this kind of milestone is not to be overlooked!

AVAI isn’t just chasing trends—it’s building within some of the largest markets in global healthcare.

See why AVAI is starting to look like an under-the-radar play in the explosive longevity and cell therapy space

We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Avant Technologies (OTCQB: AVAI). The compensation consists of up to $7,500 and was received/will be received from Interactive Offers.

This communication should not be considered as an endorsement of the securities of adviser Avant Technologies (OTCQB: AVAI) and we are not responsible for any errors or omissions in any information provided about the securities of Avant Technologies (OTCQB: AVAI) by Small Caps Daily or Interactive Offers.

We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.

This disclosure is made as of 05/15/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.

Behind the Markets

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.